Clopidogrel (Plavix)

• P2Y12 Receptor Inhibitor: Irreversibly blocks ADP-mediated platelet activation; key drug for ACS, PCI stents, and ischemic stroke/TIA prevention
• Dual Antiplatelet Therapy (DAPT): Almost always used with aspirin initially after ACS or stenting; may be used alone long term in some stroke/TIA patients or those with aspirin intolerance
• Prodrug Activation: Requires hepatic CYP enzymes (especially CYP2C19); genetic polymorphisms and drug-drug interactions can reduce active metabolite exposure and blunt effect
• Typical Dosing: 300-600 mg loading dose, then 75 mg PO daily maintenance
• Persistent Effect: Platelet inhibition persists for life of platelet (~7-10 days); no direct reversal agent—reversal relies on holding drug and sometimes transfusing platelets in major bleeding
• Cost & Availability: Compared to newer P2Y12 inhibitors (ticagrelor, prasugrel), clopidogrel is slightly less potent but cheaper, widely available, and often preferred in patients with higher bleeding risk

• Generic Name: Clopidogrel bisulfate
• Brand Names: Plavix, generics

Thienopyridine antiplatelet agent; P2Y12 receptor inhibitor

Mechanism of Action:

• Clopidogrel is a prodrug: requires hepatic biotransformation via CYP enzymes (CYP2C19, 3A4, 2B6, others) to an active thiol metabolite
• The active metabolite irreversibly binds to the P2Y12 ADP receptor on platelets, blocking ADP-mediated activation and subsequent GPIIb/IIIa receptor expression
• Prevents ADP-induced platelet aggregation, especially important in thrombus formation on disrupted atherosclerotic plaques and stents
• Because inhibition is irreversible, platelets remain inhibited for their lifespan; new platelet production restores function over 7-10 days

Pharmacokinetics:

• Absorption: Well absorbed orally; unaffected significantly by food
• Activation: ~85% of dose hydrolyzed to inactive metabolites; ~15% metabolized to active thiol via CYP2C19 and other hepatic enzymes
• Onset: With 300 mg loading dose, significant platelet inhibition at ~4-6 hours; with 600 mg loading, onset faster (~2 hours). Without loading, steady-state effect after ~3-7 days of 75 mg daily
• Elimination: Inactive metabolites excreted renally (~50%) and in feces (~50%); effective half-life of active metabolite is short, but functional effect persists due to irreversible receptor binding
• CYP2C19 Poor Metabolizers: Patients with genetic polymorphisms or those taking strong inhibitors (e.g., omeprazole) may have reduced response; some centers use alternative P2Y12 inhibitors in high-risk patients

• Acute coronary syndrome: STEMI, NSTEMI, unstable angina with PCI and stent placement as part of DAPT
• Medically managed ACS: No PCI, alongside aspirin to reduce recurrent ischemic events
• Ischemic stroke or TIA: Secondary prevention, either as monotherapy or short-course DAPT initially (e.g., clopidogrel + aspirin in minor stroke/TIA per neuro guidelines)
• Peripheral arterial disease: Symptomatic claudication or prior limb ischemia
• Aspirin intolerance: Alternative antiplatelet agent in patients with aspirin allergy

Available Forms:

• Tablets: 75 mg (most common), 300 mg loading tablets in some markets
• Crushed tablets can be given via NG/OG tube if needed; absorption remains reasonably good
• Combination products with aspirin exist but are less common in acute ICU/ED setting

Adult Dosing (Always Follow Cardiology/Neuro Protocols):

Contraindications:

• Active pathological bleeding (e.g., gastrointestinal bleeding, intracranial hemorrhage)
• Known hypersensitivity to clopidogrel or any component of the formulation

Major Precautions:

• History of intracranial hemorrhage or major GI bleeding: weigh ischemic benefit vs bleeding risk closely
• Concurrent use with other antiplatelets or anticoagulants increases bleeding risk; ensure indication is strong and duration is appropriate
• CYP2C19 poor metabolizers or patients on strong CYP2C19 inhibitors (omeprazole, esomeprazole, some SSRIs) may have reduced clopidogrel effect; consider alternative P2Y12 agents in high-risk patients
• Rare but serious thrombotic thrombocytopenic purpura (TTP): presents with thrombocytopenia, hemolytic anemia, neurologic signs, renal dysfunction, and fever

Common:

• Bleeding (epistaxis, bruising, ecchymoses)
• Gastrointestinal upset: dyspepsia, diarrhea
• Rash or pruritus

Serious:

• Major bleeding: GI bleed, intracranial hemorrhage, surgical site bleeding
• Thrombotic thrombocytopenic purpura (TTP)
• Severe neutropenia or aplastic anemia (rare)

Clinical Monitoring:

• Signs of bleeding: overt bleeding (GI, GU, surgical drains), declining hemoglobin/hematocrit, hemodynamic instability
• Neurologic status for possible intracranial hemorrhage in setting of new or worsening neurologic deficits or severe headache
• CBC and platelet count periodically in long-term therapy or if bruising/bleeding seems excessive
• Review medication list for interacting drugs (especially PPIs, SSRIs, and other antithrombotics)
• Timing of last dose before high-bleeding-risk procedures: typically held 5-7 days pre-op in elective surgery or neuraxial procedures

• 1. Lexicomp. (2024). Clopidogrel: Drug information. Wolters Kluwer.
• 2. Levine, G. N., Bates, E. R., Bittl, J. A., et al. (2016). 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. Circulation, 134(10), e123–e155. https://doi.org/10.1161/CIR.0000000000000404
• 3. Kleindorfer, D. O., Towfighi, A., Chaturvedi, S., et al. (2021). 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke, 52(7), e364–e467. https://doi.org/10.1161/STR.0000000000000375